Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

tau

- PMLiVE

Galimedix establishes Alzheimer’s Disease Scientific Advisory Board

The Board will advise Galimedix on scientific and clinical strategy

- PMLiVE

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

Cuttsy + Cuttsy

- PMLiVE

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Cuttsy + Cuttsy

- PMLiVE

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

MS affects nearly three million people worldwide and has three main types

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Pfizer announces phase 3 results for nonsegmental vitiligo treatment

Litfulo delivered significant, clinically meaningful improvements for both face and body

- PMLiVE

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Cuttsy + Cuttsy

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

Veradermics’ oral treatment for female pattern hair loss delivers positive study results

Pattern hair loss affects around 30 million women and 50 million men in the US

- PMLiVE

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Cuttsy + Cuttsy

- PMLiVE

Alzheimer’s groups call for urgent global focus on women’s brain health

New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association

- PMLiVE

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links